Lb Pharmaceuticals (LBRX) Non Operating Income (2024 - 2026)

Lb Pharmaceuticals has reported Non Operating Income for 3 years, with the latest figure at $3.0 million in Q1 2026.

• For the quarter ending Q1 2026, Non Operating Income rose 171.59% year-over-year to $3.0 million; the trailing twelve-month figure through Mar 2026 stood at $8.3 million (changed N/A YoY), and the FY2025 full-year result was $5.2 million, up 200.75% from the prior year.
• Non Operating Income for Q1 2026 stood at $3.0 million, up from $2.4 million in the prior quarter.
• The five-year high for Non Operating Income was $3.0 million in Q1 2026, with the low at $469000.0 in Q4 2024.
• Average Non Operating Income over 3 years is $1.8 million, with a median of $1.8 million recorded in 2024.
• Peak annual rise in Non Operating Income reached 411.51% in 2025, while the deepest fall reached 11.15% in 2025.
• Tracing LBRX's Non Operating Income over 3 years: stood at $469000.0 in 2024, then soared by 411.51% to $2.4 million in 2025, then advanced by 27.14% to $3.0 million in 2026.
• The last three Non Operating Income figures came in at $3.0 million (Q1 2026), $2.4 million (Q4 2025), and $1.7 million (Q3 2025), per Business Quant data.

Peer Comparison